Recent advances in liposomal dry powder formulations: Preparation and evaluation

Expert Opinion on Drug Delivery

Volumn 6, Issue 1, 2009, Pages 71-89

  Misra, Ambikanandan ^a   Jinturkar, Kaustubh ^a   Patel, Deepa ^a   Lalani, Jigar ^a   Chougule, Mahavir ^b  

^a M S UNIVERSITY OF BARODA   (India)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Dry powder formulations; Inhalers; Liposomes; Pulmonary

Indexed keywords

AMIKACIN; AMILORIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ARIKACE; BUDESONIDE; CAMPTOTHECIN; CIPROFLOXACIN; DAPSONE; DOXORUBICIN; ETHIONAMIDE; FENTANYL; FORMOTEROL; INSULIN; INTERLEUKIN 2; ISONIAZID; KETOTIFEN; KETOTIFEN FUMARATE; LACTOSE; LEUPRORELIN; LEVONORGESTREL; LIPOSOME; OPIATE; PYRAZINAMIDE; RIFAMPICIN; RUBITECAN; STREPTOMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; CHRONIC PAIN; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; DRUG TISSUE LEVEL; DRY POWDER; ENCAPSULATION; ENDOMETRIUM CANCER; EPITHELIUM CELL; FLOW MEASUREMENT; FREEZE DRYING; HUMAN; INHALER; LIPOSOMAL DELIVERY; LUNG ALVEOLUS EPITHELIUM; LUNG ASPERGILLOSIS; LUNG CANCER; LUNG CARCINOMA; LUNG GRAFT REJECTION; LUNG INFECTION; LUNG TUBERCULOSIS; MICROPHOTOGRAPHY; MOISTURE; NONHUMAN; OXIDATION; PAIN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PNEUMOCYSTIS PNEUMONIA; PROSTATE CANCER; REVIEW; SCANNING ELECTRON MICROSCOPY; SECONDARY INFECTION; SPRAY DRYING; SUPERCRITICAL FLUID; ZETA POTENTIAL; AEROSOL; ANIMAL; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; NEBULIZER; POWDER; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; LUNG; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL PREPARATIONS; POWDERS; TISSUE DISTRIBUTION;

EID: 64749110689     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802652309     Document Type: Review

References (142)

1. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995;12:151-231
2. Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006;113:9-14 (Pubitemid 43818162)
3. Shenfield GM, Evans ME, Paterson JW. Absorption of drugs by the lung. Br J Clin Pharmacol 1976;3:1218-1226
4. Byron PR. Prediction of drug residence time, in region of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986;75:433-438 (Pubitemid 16083635)
5. Metered Dose Inhalers: Devices, Drugs and Delivery Strategies, Sept 2006; Available from: http://www.greystoneassociates.org/MDIPercent20Prospectus.pdf [Last accessed 15 August 2008]
6. Joseph RL. The inhalation of drugs: Advantages and problems. Respir care 2005;50(3):367-382 (Pubitemid 46179556)
7. McCallion ONM, Taylor KMG, Taylor U, et al. Jet nebulisers for pulmonary drug delivery. Int J Pharm 1996;130:1-11 (Pubitemid 26129782)
8. Zainudin BMZ, Biddiscombe M, Spiro SG, et al. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder, and as a nebulized solution. Thorax 1990;45:469-473 (Pubitemid 20225175)
9. Dahlstrom K, Thorsson L, Nikander K, et al. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann Allergy Asthma Immunol 2003;90(2):226-232 (Pubitemid 36231746)
10. Bryson HM, Sorkin EM. Dornase alpha: a review of its pharmacological properties and therapeutic potential in cystic fibrosis. Drugs 1994;48:894-906
11. Waldrep JC, Dhand R. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 2008;5(2):114-119
12. Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmonol Dis 2006;1(3):251-259
13. Ashurst II, Malton A, Sumby B, et al. Latest advances in the development of dry powder inhalers. Pharm Sci Technol 2000;3(7):246-256 (Pubitemid 30462198)
14. Hickey AJ, Concessio NM, Platz RM, et al. Factors influencing the dispersion of dry powders as aerosols. Pharm Technol 1994;08:58-84
15. Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005;50(10):1313-1322
16. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96:293-304
17. Shek PN, Barber RF. Liposomes: a new generation of drug and vaccine carriers. Mod Med 1986;41:314-326
18. Kimelberg HK, Mayhew EG. Properties and biological effects of liposomes and their uses in pharmacology and toxicology. Crit Rev Toxicol 1978;6(1):25-79
19. Poznansky MJ, Juliano RL. Biological approaches to the controlled delivery of drugs: A critical review. Pharmacol Rev 1984;36:277-336 (Pubitemid 15189559)
20. Taylor KMG, Newton JM. Liposomes for controlled delivery of drugs to the lung. Thorax 1992;47:257-259
21. Newman SP. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther 2004;4(1):23-33 (Pubitemid 38057264)
22. Courrier HM, Butz N, Andamme F. Pulmonary Drug Delivery Systems: Developments and Prospects. Crit Rev Ther Drug Carr Syst 2002;19(4-5):425-498
23. Chengjiu Hu A, David G. Rhodes, Proniosomes: A Novel Drug Carrier Preparation. Int J Pharm 1999;185:23-35 (Pubitemid 29333093)
24. Frijlink HW, Boer AD. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv 2004;1(1):67-86 (Pubitemid 40297957)
25. Chan HK. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med 2006;19(1):21-27
26. Ashurst S, Malton A, Pstt BS, et al. Latest advances in the development of dry powder inhaler. Pharm Sci Technol Today 2000;3(7):246-256 (Pubitemid 30462198)
27. Bystrom K, Nilsson PG. Powders for inhalation. US6045828; 1996
28. Parmar M. Formulation of insoluble small molecule therapeutics in lipid-based carriers. US20060051406A1; 2006
29. Weers JG, Tarara T, Tzannis S. Lipid formulations for spontaneous drug encapsulation. US20050214224A1; 2005
30. Padhi B, Chougule M, Misra A. Optimization of formulation components and characterization of large respirable powders containing high therapeutic payload. Pharm Dev Technol 2006;11(4):465-475 (Pubitemid 44852428)
31. Bot A, Tarara T, Weers J, et al. Novel Lipid-Based Hollow-Porous Microparticles as a Platform for Immunoglobulin Delivery to the Respiratory Tract. Pharm Res 2000;17(3):275-283 (Pubitemid 30225130)
32. Katsuto O, Tomohiro, Masahiko A, et al. Development of a New Preparation Method of Liposomes Using Supercritical Carbon Dioxide. Langmuir 2001;(17):3898-4390
33. Hersey JA. Ordered mixing: a new concept in powder mixing practice. Powder Technol 1975;11:41-44
34. Newman SP, Clarke SW. Therapeutic aerosols I-physical and practical considerations. Thorax 1983;38:881-886 (Pubitemid 14213229)
35. Byron PR, Patton JS. Drug delivery via the respiratory tract. J Aerosol Med 1994;7(1):49-75 (Pubitemid 24277024)
36. Hickey AJ. Summary of common approaches to pharmaceutical aerosol administration; Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker, New York; 1992:255-288
37. Bisgaard H. Drug delivery from inhaler devices. Lung deposition, clinical effect and cost effectiveness vary. Br Med J 1996;313:895-896 (Pubitemid 26340860)
38. Hickey AJ, Concessio NM. Descriptors of irregular particle morphology and powder properties. Adv Drug Deliv Rev 1997;26(1):29-39 (Pubitemid 27288482)
39. Ganderton D. The generation of respirable cloud from coarse powder aggregates. J Biopharm Sci 1992;3:101-105
40. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 1996;27:769-783 (Pubitemid 26234318)
41. Steckel H, Muller BW. In vitro evaluation of dry powder inhalers II: Influence of carrier particle size and concentration on in passivation effects. In: Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society, London, UK 1996:86-89
42. Zeng XM, Tee SK, Marriott C, et al. Effect of mixing procedure and particle size distribution of carrier particles on the deposition of salbutamol sulphate from dry powder inhaler formulations. In Proceedings of Drug Delivery to the Lungs VII. The Aerosol Society, London, UK; 1996:40-43
43. Shah SP, Misra A. Development of liposomal Amphotericin B dry powder inhaler formulation. Drug Deliv 2004;11(4):247-253 (Pubitemid 39096043)
44. Chougule MB, Padhi BK, Misra A, et al. Development of Dry Powder Inhalers. Recent Patents Drug Deliv Formulation 2007;1:11-21
45. Shah SP, Misra A. Liposomal Amikacin Dry Powder Inhaler: Effect of Fines on In Vitro Performance. AAPS PharmSciTech 2004;5(4): E65
46. Lu D, Hickey A. Liposomal Dry Powders as Aerosols for Pulmonary Delivery of Proteins. AAPS PharmSciTech 2005;6(4):E641-8 (Pubitemid 43046101)
47. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS PharmSciTech 2005;6(3):E482-6 (Pubitemid 41631768)
48. Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech 2001;30(2):25-31 (Pubitemid 41086083)
49. Joshi M, Misra A. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin Exp Pharmacol Physiol 2003;30:153-156 (Pubitemid 36343937)
50. Shahiwala A, Misra A. Pulmonary absorption of liposomal levonorgestral. AAPS PharmSciTech 2004;5(1):E13
51. Woolfe AJ, Zheng XM, Langford A. Methods to produce powders for pulmonary or nasal administration. WO0113885; 2001
52. Bosquillona C, Rouxhetb PG, Vanbeve R, et al. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release 2004;99:357-367 (Pubitemid 39296905)
53. Kussendrager KD, Ellison MJH. Carrier material for dry powder inhalaltion. WO20020207705; 2002
54. Briscoe P, Caniggia I, Graves A, et al. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am J Physiol 1995;268:L374-80
55. Sweeney L, Wang Z, Finlay W, et al. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery. Int J Pharm 2005;305(1-2):180-185 (Pubitemid 41568373)
56. Chougule M, Padhi B, Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int J Nanomedicine 2007;2(4):675-688
57. Chougule M, Padhi B, Misra A. Development of Spray Dried Liposomal Dry Powder Inhaler of Dapsone. AAPS PharmSciTech 2008;9(1):47-53
58. Chougule M, Padhi B, Misra A. Nano-liposomal Dry Powder Inhaler of Amiloride Hydrochloride. J Nanosci Nanotech 2006;6(9-10):3001-3009 (Pubitemid 44579975)
59. Sunkara G, Kompella U. Drug Delivery Applications of Supercritical Fluid Technology. Drug Deliv Technol 1999;2:33-34 (Pubitemid 29064291)
60. Kompella U, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carrier Syst 2001;18(2):173-199
61. Kadimi US, Balasubramanian DR, Govindarajulu V, et al. In vitro studies on liposomal amphotericin B obtained by supercritical carbon dioxide-mediated process. Nanomedicine 2007;3(4):273-280
62. Misra A, Parmar N, Naik S, et al. Preparation of Amphotericin B liposomes by supercritical fluid technology, IN391/MUM/2008; 2008
63. Crompton GK, Dewar MH, Innes JA, et al. Inhaler reference and technique in inhaler native subjects; a comparison of HFA and conventional devices. Thorax 2000;55(3):A61
64. Akwete LA, Hsu L. Leuprolide and other LH-RH analogues in stability and characterization of protein and peptide drugs: case histories. In: Wang YJ, Pearlman R, eds. Formation, Characterization, and Stability of Protein Drugs. New York, NY: Plenum Press; 1993:159-199
65. Vyas SP, Quraishi S, Gupta S, et al. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005;296:12-25 (Pubitemid 40693368)
66. Kaszuba M. The Measurement of Nanoparticles Using Photon Correlation Spectroscopy and Avalanche Photo Diodes. J Nano Res 1999;1(3):405-409 (Pubitemid 129636201)
67. Goel BK. Medical Laboratory Technology. Vol.III. New Delhi, India, Tata McGraw-Hill; 1988:1031
68. Betagiri JV, Jenkins SA, Parsons DL. Liposomes Drug Delivery System. Lanchaster, Basel, Switzerland: Technomic Publishing Co Inc; 1993:120
69. New RRC. Liposomes - a practical approach. Oxford University Press; 1990:137-140
70. Kent J, Huiling M, Xuebing X, et al. Oxidative stability of Liposomes composed of docosahexaenoic acid-containing phospholipids. J Am oil chem soc 2007;84(7):631-637 (Pubitemid 47167276)
71. Mina A, Kanako Y, Kazuo M. Oxidative stability of polyunsaturated fatty acid in phaophatidylcholine liposomes. Biosci Biotechnol Biochem 2002;66(12):2573-2577 (Pubitemid 39251127)
72. New RRC. Liposomes - a practical approach. Oxford University Press; 1990:113
73. Carr RL. Evaluating flow properties of solids. Chem Eng 1965;72:163-168
74. Van WEC, Crommelin DJ. Long term stability of freeze-dried, lyoprotected doxorubicin liposomes. Eur J Pharm Biopharm 1997;43(3):295-307 (Pubitemid 28298788)
75. Singh S. Drug stability testing and shelf life determination according to international guidelines. Pharm Tech 1999;23:68-86 (Pubitemid 29282560)
76. ICH guidelines for stability testing of new drug substances and products. ICH Topic Q1A (R2); 2003:7
77. Aerosols, Nasal Sprays, Metered Dose Inhalers, and Dry Powder Inhalers. USP 30 NF; 25 2007:601-607
78. Next Generation Pharmaceutical Impactor, Applied Physics Inc Available from: http://www.appliedphysicsusa.com/ngi-moudi.html [Last accessed on 9 October 2008]
79. Mitchell J, Nagel M, Doyle C, et al. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: Comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer. AAPS PharmSciTech 2004;4(4):425-433 (Pubitemid 41086194)
80. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006;58:1030-1060
81. Enna SJ, Schanker LS. Absorption of saccharides and urea from the rat lung. Am J Physiol 1972;222:409-414
82. Wolff RK, Dorato MA. Toxicologic testing of inhaled pharmaceutical aerosols. Crit Rev Toxicol 1993;23:343-369 (Pubitemid 24010013)
83. Brian JD, Knudson DE, Davis MA, et al. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 1976;11:13-33
84. Okamoto H, Aoki M, Danjo K. A novel apparatus for rat in vivo evaluation of dry powder formulations for pulmonary administration. J Pharm Sci 2000;89:1028-1035 (Pubitemid 30692819)
85. Sakagami M, Kinoshita W, Makino Y, et al. Fractional contribution of lung, nasal and gastrointestinal absorption to the systemic level following nose-only aerosol exposure in rats: a case study of 3.7 μm fluorescein aerosols. Arch Toxicol 2003;77:321-329 (Pubitemid 36819262)
86. Joshi M, Misra A. Pulmonary disposition of budesonide from liposomal dry prowder inhaler. Meth Find Exp Clin Pharm 2001;23(10):531 (Pubitemid 34229356)
87. Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Food and Drug Administration, Rockville, MD, 2000. Available from: http:// www.fda.gov/cder/guidance/index.htm [Last assessed on 1 August 2008]
88. Amidon GL, Lennernas H, Crison JR, et al. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-420
89. Dobbs LG. Isolation and culture of alveolar type II cells. Am J Physiol 1990;258:L134-47
90. Cheek JM, Evans MJ, Crandall ED. Type I cell-like morphology in tight alveolar epithelial monolayers. Exp Cell Res 1989;184:3753-3787
91. Dodoo ANO, Bansal SS, Marriott C, et al. Use of alveolar cell monolayers of varying electrical resistance to measure pulmonary peptide transport. J Pharm Sci 2000;89:223-231 (Pubitemid 30120802)
92. Fang X, Song Y, Matthay MA, et al. Transport across cultured rat alveolar epithelial cells: a novel in vitro system. Am J Physiol 2004;27:L104-L110 (Pubitemid 38787656)
93. Elbert KJ, Schafer UF, Lehr CM, et al. Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharm Res 1999;16:601-608 (Pubitemid 29227086)
94. Fuchs S, Hollins AJ, Lehr CM, et al. Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell Tissue Res 2003;311:31-45 (Pubitemid 35478222)
95. Anabousi S, Bakowsky U, Ehrhardt C, et al. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur J Pharm Sci 2006;29:367-374
96. Sakagami M, Byron PR, Venitz J, et al. Solute disposition in the rat lung in vivo and in vitro: determining regional absorption kinetics in the presence of mucociliary clearance. J Pharm Sci 2002;91:594-694 (Pubitemid 34137376)
97. Pang Y, Sakagami M, Byron PR. The pharmacokinetics of pulmonary insulin in the isolated perfused rat lung: implications of metabolism and regional deposition. Eur J Pharm Sci 2005;25:369-378 (Pubitemid 40853864)
98. Tronde A, Norden B, Bengtsson UH, et al. Drug absorption from the isolated perfused rat lung-correlations with drug physicochemical properties and epithelial permeability. J Drug Target 2003;11(1):61-74 (Pubitemid 36527397)
99. Patel G, Misra A. Pulmonary Delivery of liposomal Dry Powder Inhaler of Formoterol for effective treatment of Asthma. Available from: http://www.aapspharmsci.org/abstracts/AM-2007/AAPS2007-001080.PDF [Last accessed on 29 August 2008]
100. Joshi M, Misra A. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization. Int J Pharm 2001;223(1-2):15-27 (Pubitemid 32640874)
101. Onoue S, Yamada S, Yajima T. Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. Peptides 2007;28(9):1640-1650 (Pubitemid 47361420)
102. Hajos F, Stark B, Mosgoeller W, et al. Inhalable liposomal formulation for vasoactive intestinal peptide. Int J Pharm 2008;357(1-2):286-294
103. Omri A, Beaulac C, Lagacé J, et al. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38(5):1090-1095 (Pubitemid 24150843)
104. Mugabe C, Azghani AO, Omri A. Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemother 2005;55(2):269-271 (Pubitemid 40331158)
105. Farr SJ, Otulana BA. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev 2006;58(9-10):1076-1088 (Pubitemid 44709267)
106. Changsan N, Srichana T. Factors Influencing the Properties of Rifampicin Liposome and Applications for Dry Powder Inhaler. Nano/Micro Engineered and Molecular Systems. 2nd IEEE International Conference. 16-19 January; 2007:1104-1109
107. Changsan N, Chan HK, Srichana T, et al. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 2008 May 15. DOI:10.1002/jps.21441 [Epub ahead of print]
108. Justo OR, Moraes AM. Incorporation of Antibiotics in Liposomes Designed for Tuberculosis Therapy by Inhalation. Drug Deliv 2003;10(3):201-207 (Pubitemid 36993372)
109. Liu F, Shao Z, Mitra AK. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993;10:228-232 (Pubitemid 23041736)
110. Huang Y, Wang C. Pulmonary delivery of insulin by liposomal carriers. J Control Release 2006;113:9-14; (Pubitemid 43818162)
111. Ten RM, Anderson PM, Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2002;(2):333-344
112. Lo YL, Tsai JC, Kuo JH. Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J Control Release 2004;94(2-3):259-272 (Pubitemid 38117138)
113. Schreier HANS. Liposome Powders. WO1994028876; 1994
114. Misra A, Padhi BK, Chougule MB. Engineered Monodisperse Inhalation Powders for Effective Treatment of Lung Diseases, IN228/MUM/2005; 2005
115. Misra A, Padhi BK, Chougule MB, et al. Aerodynamically light porous dry powder inhaler formulations for targeted pulmonary deposition, IN953/MUM/2006; 2006
116. Frank P. An Inhalation System. EP1128813; 2001
117. Roman PS, Frank P. Methods for treating lung cancer. WO03015707A2; 2003
118. Bystrom K, Nilsson P. Powders for inhalation. US6045828; 1996
119. Weers JG, Tarara T, Tzannis S. Lipid formulations for spontaneous drug encapsulation. US20050214224A1; 2005
120. Huang L, Sorgi, Frank L. A Dry Powder Formulation For Gene Delivery. WO1996027393; 1996
121. Taylor P, William M, Janet C. Liposomes Containing A Corticosteroids. WO1996022764; 1996
122. Wang Z, Orszanska H, Finlay W. Spray freeze dried liposomal ciprofloxacin powder aerosol drug delivery. US20060280691; 2006
123. Walter PR, Vladimir M, Paul MR. Formulations of DNAse and Methods of use thereof. WO2008039989; 2008
124. Clark A, Shire SJ. Pulmonary delivery technology: recent advances and potential for the new millennium. Pharmaceutical Inhalation Aerosol Technology. Marcel Dekker; NY; 2004:571-592
125. Lema G, Dryja D, Vargas I, Enhorning G. Pseudomonas aeruginosa from Patients with Cystic Fibrosis Affects Function of Pulmonary Surfactant. Pediatric Res 2000;47:121-126 (Pubitemid 30038901)
126. Multidose Safety and Tolerability Study of (Arikace™) for Inhalation In Cystic Fibrosis Patients. Transave NCT00558844. November 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00558844?intr =%22Amikacin%22&rank=9 [Last Accessed on 1 September 2008;]
127. Aradigm Reports Successful Top-Line Phase 2 Data With Inhaled Liposomal Ciprofloxacin For Cystic Fibrosis. Available from: http://www.medicalnewstoday. com/articles/113831.php [Last accessed on 1 September 2008]
128. Aradigm Initiates Phase 2 Study of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Available from: http://www.reuters.com/article/pressRelease/ idUS103481+19-Jun-2008+BW2008061 9 [Last accessed on 1 September 2008]
129. Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis (AMBINEB). PETHEMA Foundation NCT00391014. April 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00391014?term= NCT00391014&rank=1 [Last accessed on 1 September 2008]
130. Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study University of Pittsburgh Astellas Pharma US, Inc NCT00177710, Dec 2007. Available from: http://clinicaltrials.gov/ct2/ show/NCT00177710?term=liposomes+pulmonary&rank=3 [Last accessed on 1 September 2008]
131. Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis. Erasmus Medical Center, Gilead Sciences, Nexstar Pharmaceuticals, NCT00263315 May 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00263315?term= liposome+inhalation&rank=2 [Last accessed on 1 September 2008]
132. Aerosolized Liposomal Camptothecin in Patients With Metastatic or Recurrent Cancer of the Endometrium or the Lung. University of New Mexico NCT00277082. -ANY-. Available from: http://clinicaltrials.gov/ct2/show/ NCT00277082?term=liposome+aerosol&rank=2[Last accessed on 1 September 2008]
133. Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) University of New Mexico. NCT00250068. June 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00250068?term=liposome+aerosol&rank= 3 [Last accessed on 1 September 2008]
134. Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC). University of New Mexico. NCT00249990 June 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00249990?term=liposome+aerosol&rank=4 [Last accessed on 1 September 2008]
135. Skubitz K, Anderson P. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Clinical report. AntiCancer Drugs 2000;11(7):555-563 (Pubitemid 30740433)
136. Study of Single and Multiple Doses of Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Healthy Subjects (LEF-2495). YM BioSciences NCT00709254. Jan 2002. Available from: http://clinicaltrials.gov/ct2/show/ NCT00709254?term=liposome+inhalation&rank=3 [Last accessed on 1 September 2008]
137. Study Evaluating Inhaled AeroLEF (Liposome-Encapsulated Fentanyl)in Normal Healthy Subjects. YM BioSciences. NCT00708318. June 2002. Available from: http://clinicaltrials.gov/ct2/show/NCT00708318?term= liposome+inhalation&rank=4 [Last accessed on 1 September 2008]
138. Ferin J, et al. Pulmonary retention of ultrafine and fine particles in rats. Am J Resp Cell Mol Biol 1992;6:535-542
139. Li X, et al. Short-term inflammatory responses following intratracheal instillations of fine and ultrafine carbon black in rats. Inhal Toxicol 1995 ;(11):709-731
140. Wolff RK, Dorato MA. Toxicologic Testing of Inhaled Pharmaceutical Aerosols'. Crit Rev Toxicol 1993;23(4):343-369 (Pubitemid 24010013)
141. Jong W, Borm P. Drug delivery and nanoparticles: Applications and hazards. Int J Nanomedicine 2008;3(2):133-149 (Pubitemid 352042401)
142. Henderson RF. Bronchoalveolar lavage: a tool for assessing the health status of the lung, in Concepts in Inhalation Toxicology. In: McClellan R, Hcnderson RF, editors, Hemisphere, New York; 1988. p. 415